Hiroshi Saijo

569 total citations
18 papers, 383 citations indexed

About

Hiroshi Saijo is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Hiroshi Saijo has authored 18 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Hiroshi Saijo's work include Immunotherapy and Immune Responses (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (5 papers). Hiroshi Saijo is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (5 papers). Hiroshi Saijo collaborates with scholars based in Japan and Canada. Hiroshi Saijo's co-authors include Naoto Hirano, Tingxi Guo, Kenji Murata, Kenji Sugata, Kayoko Saso, Chung-Hsi Wang, Yuki Kagoya, Mark Anczurowski, Yukiko Matsunaga and Marcus O. Butler and has published in prestigious journals such as Nature Biotechnology, The Journal of Immunology and PLoS ONE.

In The Last Decade

Hiroshi Saijo

18 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Saijo Japan 10 230 198 155 68 42 18 383
Malvina Prapa Italy 7 198 0.9× 139 0.7× 87 0.6× 47 0.7× 83 2.0× 10 350
Christian Augsberger Germany 5 282 1.2× 180 0.9× 197 1.3× 58 0.9× 22 0.5× 9 484
Jiage Ding China 11 300 1.3× 128 0.6× 227 1.5× 44 0.6× 60 1.4× 18 414
Annelisa M. Cornel Netherlands 9 245 1.1× 164 0.8× 229 1.5× 37 0.5× 27 0.6× 16 439
Carla A. Jaeger-Ruckstuhl United States 7 244 1.1× 99 0.5× 154 1.0× 47 0.7× 77 1.8× 12 341
Rebecca Wijers Netherlands 8 245 1.1× 89 0.4× 174 1.1× 31 0.5× 37 0.9× 13 337
Stina L. Wickström Sweden 14 344 1.5× 145 0.7× 367 2.4× 49 0.7× 78 1.9× 20 575
Daniel Michaud United States 7 384 1.7× 117 0.6× 313 2.0× 57 0.8× 85 2.0× 11 527
Sanaz Taromi Germany 9 305 1.3× 156 0.8× 139 0.9× 62 0.9× 77 1.8× 13 422
Antonio Valeri Spain 12 294 1.3× 124 0.6× 303 2.0× 60 0.9× 28 0.7× 23 462

Countries citing papers authored by Hiroshi Saijo

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Saijo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Saijo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Saijo more than expected).

Fields of papers citing papers by Hiroshi Saijo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Saijo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Saijo. The network helps show where Hiroshi Saijo may publish in the future.

Co-authorship network of co-authors of Hiroshi Saijo

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Saijo. A scholar is included among the top collaborators of Hiroshi Saijo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Saijo. Hiroshi Saijo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Tokita, Serina, Toshiyuki Sumi, Hiroshi Saijo, et al.. (2025). Loss of Tapasin in Tumors Potentiates T‐Cell Recognition and Anti‐Tumor Effects of Immune Checkpoint Blockade. Cancer Science. 116(5). 1203–1213. 1 indexed citations
2.
Saijo, Hiroshi, Yoshihiko Hirohashi, Toyohiro Saikai, et al.. (2023). Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor. Anticancer Research. 43(9). 4155–4160. 4 indexed citations
3.
Murata, Kenji, Dalam Ly, Hiroshi Saijo, et al.. (2022). Modification of the HLA-A*24:02 Peptide Binding Pocket Enhances Cognate Peptide-Binding Capacity and Antigen-Specific T Cell Activation. The Journal of Immunology. 209(8). 1481–1491. 2 indexed citations
4.
Sugata, Kenji, Yukiko Matsunaga, Yūki Yamashita, et al.. (2021). Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Nature Biotechnology. 39(8). 958–967. 14 indexed citations
5.
Kagoya, Yuki, Tingxi Guo, Brian Yeung, et al.. (2020). Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. Cancer Immunology Research. 8(7). 926–936. 126 indexed citations
6.
Anczurowski, Mark, Kenji Sugata, Yukiko Matsunaga, et al.. (2019). Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87. Journal of Autoimmunity. 102. 114–125. 2 indexed citations
7.
Kagoya, Yuki, Hiroshi Saijo, Yukiko Matsunaga, et al.. (2018). Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells. Journal of Autoimmunity. 97. 10–21. 38 indexed citations
8.
Yamada, Gen, Hirofumi Chiba, Aki Ishikawa, et al.. (2018). A new ENG mutation in a Japanese family with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Respiratory Medicine Case Reports. 25. 73–77. 1 indexed citations
9.
Hirohashi, Yoshihiko, Tasuku Mariya, Takeshi Suzuki, et al.. (2017). Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy. PLoS ONE. 12(3). e0171460–e0171460. 18 indexed citations
10.
Hasegawa, Yoshihiro, Mitsuo Otsuka, Shigeru Ariki, et al.. (2017). Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients. Oncogene. 36(46). 6432–6445. 27 indexed citations
11.
Kanaseki, Takayuki, Serina Tokita, Ayumi Hongo, et al.. (2017). Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. OncoImmunology. 6(2). e1274476–e1274476. 48 indexed citations
12.
Saijo, Hiroshi, et al.. (2017). Occult Thyroid Follicular Carcinoma Diagnosed as Metastasis to the Chest Wall. Internal Medicine. 56(15). 2033–2037. 4 indexed citations
13.
Hirohashi, Yoshihiko, Aiko Murai, Rena Morita, et al.. (2016). Establishment and Analysis of Cancer Stem-Like and Non-Cancer Stem-Like Clone Cells from the Human Colon Cancer Cell Line SW480. PLoS ONE. 11(7). e0158903–e0158903. 9 indexed citations
14.
Hirohashi, Yoshihiko, Toshihiko Torigoe, Tasuku Mariya, et al.. (2016). Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy. Oncotarget. 7(10). 11223–11237. 42 indexed citations
15.
Mariya, Tasuku, Yoshihiko Hirohashi, Toshihiko Torigoe, et al.. (2016). Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer. Oncotarget. 7(18). 26806–26822. 33 indexed citations
16.
Takahashi, Akari, Yoshihiko Hirohashi, Toshihiko Torigoe, et al.. (2013). Ectopically Expressed Variant Form of Sperm Mitochondria-Associated Cysteine-Rich Protein Augments Tumorigenicity of the Stem Cell Population of Lung Adenocarcinoma Cells. PLoS ONE. 8(11). e69095–e69095. 12 indexed citations
17.
Saijo, Hiroshi, et al.. (2013). A Case of Crizotinib-induced Esophagitis in a Patient with EML4-ALK-positive Lung Adenocarcinoma. Haigan. 53(7). 840–845. 1 indexed citations
18.
Kawata, Hiroshi, et al.. (1991). Software testing. 14(3). 246–253. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Malvina Prapa Breakdown of academic impact, for papers by Christian Augsberger Breakdown of academic impact, for papers by Jiage Ding Breakdown of academic impact, for papers by Annelisa M. Cornel Breakdown of academic impact, for papers by Carla A. Jaeger-Ruckstuhl Breakdown of academic impact, for papers by Rebecca Wijers Breakdown of academic impact, for papers by Stina L. Wickström Breakdown of academic impact, for papers by Daniel Michaud Breakdown of academic impact, for papers by Sanaz Taromi Breakdown of academic impact, for papers by Antonio Valeri
Rankless by CCL
2026